Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Changping Laboratory, Beijing, 102206, China.
Front Med. 2022 Apr;16(2):185-195. doi: 10.1007/s11684-021-0913-y. Epub 2022 Feb 28.
The record speed at which Chinese scientists identified severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) and shared its genomic sequence with the world, has greatly facilitated the development of coronavirus disease (COVID-19) diagnostics, drugs, and vaccines. It is unprecedented in pandemic control history to develop a dozen successful vaccines in the first year and to immunize over half of the global population in the second year, due to the efforts of the scientific community, biopharmaceutical industry, and regulatory agencies worldwide. The challenges are both great and multidimensional due to the rapid emergence of virus variants and waning of vaccine immunity. Vaccination strategies need to adapt to these challenges to keep population immunity above the herd immunity threshold, by increasing vaccine coverage, especially for older adults and young people, and providing timely booster doses with homologous or heterologous vaccine boosts. Further research should be undertaken to develop more effective vaccines against SARS-CoV-2 variants and to understand the best prime-boost vaccine combinations and immunization strategies to provide sufficient and sustainable immune protection against COVID-19.
中国科学家以创纪录的速度鉴定出严重急性呼吸综合征冠状病毒 2(SARS-CoV-2),并与世界分享其基因组序列,这极大地促进了冠状病毒病(COVID-19)诊断、药物和疫苗的研发。由于全球科学界、生物制药行业和监管机构的共同努力,在第一年开发出十几种成功的疫苗,并在第二年为全球一半以上的人口接种疫苗,这在大流行控制史上是前所未有的。由于病毒变异的迅速出现和疫苗免疫力的下降,面临的挑战是巨大的和多方面的。接种策略需要适应这些挑战,通过增加疫苗接种覆盖率,特别是为老年人和年轻人接种疫苗,并及时提供同源或异源疫苗加强针,使人群免疫力保持在群体免疫阈值以上。应进一步开展研究,开发针对 SARS-CoV-2 变异株的更有效的疫苗,并了解最佳的初始-加强疫苗组合和免疫策略,以提供针对 COVID-19 的充足和可持续的免疫保护。